Bronchodilators is the medication that is taken to improve breathing and are used for treating breathing related symptoms that are associated with allergic reaction. It is also used for expanding the airways and improving the breathing capacity function of patients with chronic obstructive pulmonary disease (COPD), bronchial asthma, emphysema, and other lung diseases. Bronchodilators function by relaxing the muscle surrounding the airways. These products are available over the counter or requires prescription. Basically there are available in three forms injectable, oral and inhaled. In oral forms they come in variety such as liquids, tablets and capsules, these oral forms are delivered in higher doses which is directly absorbed into the bloodstream and so they have relatively more side effects. Whereas inhaled once are directly deposited in the lungs causing less side effects. Bronchodilators are of basically-acting or long-acting beta2-agonists and anticholinergic agents or theophylline. They function so as to control asthma and COPD. Short acting bronchodilators function for fast relief of asthma symptoms and long acting bronchodilators function for control symptoms of asthma.
Increase in prevalence of pulmonary disorders, smoking, and junk food fuel the bronchodilators market growth. In addition, rise in disposable income, geriatric population, and increase in awareness of healthcare among population are anticipated to boost the market growth. However, side effects associated with bronchodilators and government regulations related to the safety & efficacy of the bronchodilators hinder the market. Ongoing R&D activities related to bronchodilators are anticipated to present new opportunities for the market.
North America is expected to be the largest market for bronchodilators due to high incidence rate of diseases such as COPD and asthma, high demand for bronchodilator drugs, and increase in awareness. Europe holds the second largest market share. The Asia Pacific market is expected to provide a lucrative opportunity during the forecast period due to increasing disease burden, growing biopharmaceutical industry, and rising research activity along with competitive landscape in the pharmaceutical industry. The market in Latin America and Middle East & Africa is anticipated to grow owing to increasing health care infrastructure and growing public-private collaboration to expand the health care sector.
The global Bronchodilators market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Bronchodilators volume and value at global level, regional level and company level. From a global perspective, this report represents overall Bronchodilators market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Bronchodilators in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Bronchodilators manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
AstraZeneca
Boehringer Ingelheim
GlaxoSmithKline
F. Hoffmann-La Roche
...
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Anticholinergic Bronchodilators
Adrenergic Bronchodilators
Bronchodilator Combinations
Methylxanthines
Segment by Application
Asthma
COPD
Others
Summary:
Get latest Market Research Reports on Bronchodilators . Industry analysis & Market Report on Bronchodilators is a syndicated market report, published as Global Bronchodilators Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Bronchodilators market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.